WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

Overview of new DDDs decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the DDDs from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDD will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)DDDUnit Adm.routeDeadline for objection to temporary DDDs 1) Implementation in ATC/DDD index if no objection is received
J01DD64cefpodoxime and beta-lactamase inhibitor0.42)OFinal2020
A16AX09glycerol phenylbutyrate15gOFinal2020
G04BX15pentosan polysulfate sodium0.3gOFinal2020
J01MA12levofloxacin0.24gInhal.solutionFinal2020
J04AA03calcium aminosalicylate15gOFinal2020
J04AB06enviomycin1gPFinal2020
J05AB03vidarabine0.7gPFinal2020
J05AH03peramivir0.6gPFinal2020
J05AP06asunaprevir0.2gOFinal2020
J05AP11grazoprevir0.1gOFinal2020
J05AX26amenamevir0.4gOFinal2020
J05AX27favipiravir1.6gOFinal2020
L02BB05apalutamide0.24gOFinal2020
V03AE10sodium zirconium cyclosilicate7.5gOFinal2020
J01AA14sarecycline0.1 gO01.09.20192020
J01AA15omadacycline0.3gO01.09.20192020
J01AA15omadacycline0.1 gP01.09.20192020
J05AG06doravirine0.1gO01.09.20192020
M04AB05lesinurad0.2gO01.09.20192020
P01CA03fexinidazole1.44gO01.09.20192020
A04AD11nabilone3mgOFinal2020
A10BJ06semaglutide0.11mgPFinal2020
A16AB17cerliponase alfa21mgPFinal2020
J05AH04laninamivir40mgInhal.powderFinal2020
J05AP10elbasvir50mgOFinal2020
L04AB07opinercept7mgPFinal2020
L04AC12brodalumab15mgPFinal2020
M03BX03pridinol6mgOFinal2020
N02CD01erenumab 3)2.5mgPFinal2020
G03XX01prasterone6.5mgV01.09.20192020
J05AX25baloxavir marboxil40mgO01.09.20192020
N02CD02galcanezumab 4)4mgP01.09.20192020
N02CD03fremanezumab 5)7.5mgP01.09.20192020
1) Final: indicates that the date for objection has expired.
2) Refers to cefpodoxime. Decided at the meeting in the WHO ATC/DDD Working Group in March 2018.
3) ATC code altered from N02CX07. New ATC 4th level N02CD valid from January 2020.
4) ATC code altered from N02CX08. New ATC 4th level N02CD valid from January 2020.
5) New ATC 4th level N02CD valid from January 2020.

Last updated: 2019-05-02